BHIVA 2001 guidelines: drafts now available for comment

Keith Alcorn
Estimated reading time 1 minutes
This article is more than 25 years old.

The following guidelines sections have been re-drafted and supplied for posting; others will follow later this week. Please note that full references are not available for all drafts.

Evidence

When to start (please note that this section has been extensively revised)

Glossary

salvage therapy

Any treatment regimen used after a number of earlier regimens have failed. People with HIV who have experienced side-effects and/or developed resistance to many HIV drugs receive salvage therapy, sometimes consisting of a large number of medications.

toxicity

Side-effects.

mitochondrial toxicity

Mitochondria are structures in human cells responsible for energy production. When damaged by anti-HIV drugs, this can cause a wide range of side-effects, including possibly fat loss (lipoatrophy).

metabolism

The physical and chemical reactions that produce energy for the body. Metabolism also refers to the breakdown of drugs or other substances within the body, which may occur during digestion or elimination.

lipodystrophy

A disruption to the way the body produces, uses and distributes fat. Different forms of lipodystrophy include lipoatrophy (loss of subcutaneous fat from an area) and lipohypertrophy (accumulation of fat in an area), which may occur in the same person.

What to start with

Initial failure

Adherence

Salvage therapy

Resistance

Metabolic complications of therapy: Mitochondrial toxicity

Lipodystrophy

Therapeutic drug monitoring

Process for revising the BHIVA adult antiretroviral treatment guidelines, 2001

These drafts will be revised before April 24 by the Writing Committee, after which a new draft will be made available for online discussion.

Please send any further comments to Dr Anton Pozniak.

Comments will be integrated into a second draft for discussion.

Print